HR Execs on the Move

FinThrive

www.finthrive.com

 
We`re FinThrive and we believe revenue management technology will drive the future of healthcare. We pave the way for a healthcare system that ensures every transaction and patient experience is addressed holistically. FinThrive creates integrated technology that adapts with healthcare professionals – freeing them from complexity and inefficiency so they can focus on doing their best work. Our end-to-end revenue management platform provides financial teams and stakeholders with greater reliability and control to deliver better outcomes for everyone. With our vision, technology, experience and scale, we`re advancing the healthcare economy.
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.finthrive.com
  • 200 North Point Center East Suite 400
    Alpharetta, GA USA 30022
  • Phone: 855.828.3148

Executives

Name Title Contact Details
Greg Lanier
 Chief Growth Officer Profile

Similar Companies

OneLegacy

OneLegacy is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SouthPaw Marketing Communications

SouthPaw Marketing Communications is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Professional Dynamics

Professional Dynamics is a Folsom, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Integrity Digital Solutions

Integrity Digital Solutions is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Temple, TX. To find more information about Integrity Digital Solutions, please visit www.integrityemr.com

Kolltan

Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.